These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 786645)

  • 1. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.
    Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V
    Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors.
    Mechl Z; Rovný F; Sopková B
    Neoplasma; 1977; 24(4):411-4. PubMed ID: 904743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [VM-26 salvage therapy for refractory or recurrent germinal testicular cancers].
    Miki T; Oda H; Saiki S; Kinouchi T; Kuroda M; Kiyohara H; Usami M; Kotake T
    Hinyokika Kiyo; 1985 Sep; 31(9):1649-56. PubMed ID: 4083220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
    Rivera G; Green A; Hayes A; Avery T; Pratt C
    Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma.
    Schulman CC; Rozencweig M; Staquet M; Kenis Y; Sylvester R
    Eur Urol; 1976; 2(6):271-3. PubMed ID: 829223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
    Rodriguez LH; Johnson DE; Holoye PY; Samuels ML
    Cancer Treat Rep; 1977; 61(1):87-8. PubMed ID: 324624
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
    Gad-el-Mawla NM; Muggia FM; Hamza MR; El-Morsi B; Sherif M; Mansour MA; Khafagy M; El-Sebai IT
    Cancer Treat Rep; 1978 Jul; 62(7):993-6. PubMed ID: 99234
    [No Abstract]   [Full Text] [Related]  

  • 9. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract].
    Aso Y; Ushiyama T; Suzuki K; Tajima A; Naide Y; Ohshima S; Matsuura O; Fukushima M; Ota K; Ono Y
    Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1046-51. PubMed ID: 3418215
    [No Abstract]   [Full Text] [Related]  

  • 10. Recruitment-chemoradiotherapy with VM 26 (epipodophyllotoxin) for induction treatment of malignant brain tumours.
    Yamamoto H; Shitara N; Takakura K; Sano K
    Acta Neurochir Suppl (Wien); 1979; 28(2):616-8. PubMed ID: 290264
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of etoposide for urogenital tumors].
    Kinjo T; Murase T; Aota Y; Shimoji T; Mitsuya H
    Gan To Kagaku Ryoho; 1985 Jun; 12(6):1267-71. PubMed ID: 4004290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of etoposide for pulmonary metastases from urogenital tract cancer].
    Fujita K; Murayama T; Sayama T
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2438-41. PubMed ID: 6497402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of VM-26 as a single agent in the treatment of renal carcinoma.
    Hire EA; Samson MK; Fraile RJ; Baker LH
    Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
    Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
    Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
    [No Abstract]   [Full Text] [Related]  

  • 16. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 17. Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study.
    Eur Urol; 1976; 2(3):138-41. PubMed ID: 70352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of urologic metastases].
    Zanoni F; Piva L; Milani A; Salvioni R; Faustini M; Nicolai N; Mangiarotti B; Pizzocaro G
    Arch Ital Urol Nefrol Androl; 1992 Mar; 64(1):37-43. PubMed ID: 1570524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VM-26 as a second drug in the treatment of brain gliomas.
    Kessinger A; Lemon HM; Foley JF
    Cancer Treat Rep; 1979 Mar; 63(3):511-2. PubMed ID: 427830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.